ZG 003
Alternative Names: ZG003Latest Information Update: 28 Sep 2022
Price :
$50 *
At a glance
- Originator Suzhou Zelgen Biopharmaceuticals
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in China
- 01 Aug 2018 Preclinical trials in Chronic obstructive pulmonary disease in China (unspecified route) before August 2018 (Suzhou Zelgen Biopharmaceuticals Pipeline)